Niem Malo suffered a massive heart attack at 47 that destroyed half his heart muscle. He was told his time was up. This is what he did next, and what his life looks like today.
There is a sentence that changes everything. For Niem Malo, a restaurant owner in Naples, Florida, that sentence came from a cardiologist who had just finished reviewing the damage from his heart attack.
"Your goose is cooked," the doctor told him. "You have about a year."
Niem was 47 years old. Half of his heart muscle had died. The attack had come on suddenly, and it had taken 12 hours for medical help to reach him. By the time he arrived at the hospital, the damage was catastrophic. His ejection fraction, the measure of how efficiently his heart pumped blood, had fallen to 28%. Normal is above 55%.
He was given an implanted defibrillator. He was told to get his affairs in order.
He sat with that. He thought about his restaurant, the staff who depended on him, his wife, what a year actually meant when you counted the days. Then he and his wife made a decision together: they were not going to accept that answer without looking harder.
"I was nearly bedridden. My wife had to push me through the airport in a wheelchair. I didn’t know if I was going to survive the flight."
Niem and his wife refused to accept the prognosis as the final word. They began researching every available option. What they found, through a patient advocate named Cher, was a clinical program studying an investigational autologous stem cell therapy for ischemic heart disease.
The program was early. At the time Niem enrolled, fewer than 60 people in the world had undergone the procedure. He would be the 57th.
He was so ill that the 30-hour journey to the treatment centre nearly finished what the heart attack had started. He needed a wheelchair through every airport. He arrived exhausted. But he arrived.
The process was precise and carefully sequenced. Here is what happened, in the order it happened.
First, doctors drew approximately a pint of his blood. The sample was sent to a specialized laboratory, where his own angiogenic stem cells were isolated and cultured, expanded from a very small number of cells to approximately 5 million. The entire expansion process took several days.
The cells were then returned and delivered: injected into the groin area and directly into the cardiac tissue within a 24-hour window to preserve cell viability. There were approximately ten physicians in the room during the procedure. Many were there to observe, learning this emerging approach alongside the team performing it.
Then Niem went home to Florida to wait.
Within two weeks of returning to the United States, Niem began regular stress tests with his local cardiologist in Naples. The early results showed nothing remarkable. This is consistent with how biological therapies work: the cells need time to establish, release growth factors, and stimulate new vessel formation. There is no immediate mechanical result.
But over the following months, something began to change. His cardiologist started seeing what he described as color returning to the areas of Niem’s heart that had been dark on imaging. Blood flow was reaching tissue that had not been perfused in months.
|
Niem’s cardiac outcomes over the months and years following treatment: Ejection fraction improved from 28% to 42%, moving from severely reduced to near-normal range New tissue growth and new blood vessel formation observed within three months Heart function improved to the point that his implanted defibrillator was turned off because it kept triggering on normal activity No major cardiac intervention required for over 16 years following the procedure |
"The defibrillator kept going off because I was moving too fast. They had to turn it off. My heart didn’t need it anymore."
Niem Malo is now in his mid-sixties. He works seven days a week at his restaurant in Naples, Florida. He describes himself as fully healthy. His primary reference point for the experience is not medical: it is financial and familial. He invested approximately $50,000 in the treatment. He says it is the best investment he ever made. Not because of what it cost, but because of what it bought: the ability to keep working, keep providing, and keep showing up for his family.
He talks about it the way he talks about the body’s ability to heal a cut: the biology already knows what to do. What the therapy did was amplify and direct what his own cells were already capable of, giving them the numbers and the instruction to go where healing was most needed.
"It’s like the body healing a cut, but exacerbated by science. Your own cells, doing what they are built to do, just more of them, and pointed in the right direction."
Niem Malo did not have to tell this story publicly. He chose to. He speaks at seminars and patient events because he remembers what it felt like to be the person sitting across from a doctor who has just told you that you have a year left.
He wants that person to know that he heard the same sentence, and that he is writing this 16 years later.
That is not a promise that the same outcome will happen for anyone else. Medicine does not work that way, and Niem knows it. What it is, is evidence that the conversation is worth having before accepting that the answer is final.
|
Important note on Niem’s experience: ACP-01 is investigational and not approved by Health Canada, the FDA, or any other regulatory authority for the treatment of cardiomyopathy, heart failure, or any other condition. Individual outcomes vary significantly. Niem’s experience does not represent a typical or guaranteed result. This account is drawn from Niem Malo’s own shared experience and is published with his knowledge and consent. |
|
If Niem’s story raises questions about your own situation The Hemostemix clinical team works with patients facing ischemic cardiomyopathy, heart failure, refractory angina, and advanced vascular disease. If you want to understand whether an investigational approach may be relevant to your specific history, our clinical team reviews every inquiry personally. Email: clawrence@hemostemix.com Call: +1 (239) 341-5842 Book: hemostemix.com/book-croom |
|
Disclaimer: ACP-01 is investigational and not approved by Health Canada, the FDA, or any other regulatory authority for the treatment of any condition. This article is educational only and does not constitute medical advice. Individual outcomes vary and cannot be predicted. Always consult your physician before making any treatment decisions. |